Prolonged QT interval, syncope, and delirium with galantamine

Annals of Pharmacotherapy

Volumn 42, Issue 2, 2008, Pages 278-283

  Fisher, Alexander A ^a,b   Davis, Michael W ^b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b CANBERRA HOSPITAL   (Australia)

Author keywords

Delirium; Galantamine; Prolonged QT interval; Syncope

Indexed keywords

DONEPEZIL; ENOXAPARIN; GALANTAMINE; HALOPERIDOL; IRBESARTAN; RIVASTIGMINE;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD CELL COUNT; BRADYCARDIA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; DELIRIUM; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; HEART ARREST; HEART ARRHYTHMIA; HEART BUNDLE BRANCH BLOCK; HEART INFARCTION; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPOTENSION; MALE; NAUSEA; PRIORITY JOURNAL; QT PROLONGATION; RETREATMENT; SHOCK; SIDE EFFECT; SUDDEN DEATH; SYMPTOMATOLOGY; SYNCOPE; VOMITING;

AGED, 80 AND OVER; DELIRIUM; GALANTAMINE; HUMANS; LONG QT SYNDROME; MALE; SYNCOPE;

EID: 39049155646     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K514     Document Type: Article

References (25)

1. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006:CD005593.
2. Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer's disease. Am J Med 2007;120:388-97.
3. Arias E, Gallego-Sandin S, Villarroya M, Garcia AG, Lopez MG. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther 2005;315:1346-53.
4. Thompson S, Lanctot KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf 2004;3:425-40.
5. Rowland JP, Rigby J, Harper AC, Rowland R. Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol. Adv Psych Treat 2007;13:178-84.
6. Suleyman T, Tevfik P, Abdulkadir G, Ozlem S. Complete atrioventricular block and ventricular tachyarrhythmia associated with donepezil. Emerg Med J 2006;23:641-2.
7. Nelson MW, Buchanan RW. Galantamine-induced QTc prolongation (letter). J Clin Psychiatry 2006;67:166-7.
8. Walsh E, Dourish J. Prolonged QT interval with rivastigmine (letter). Br J Psychiatry 2002;180:466.
9. Luo S, Michler K, Johnston P, Macfarlane PW. A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol 2004;37(suppl):81-90.
10. Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electrocardiol 2007;40:228-34.
11. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006:CD001747.
12. Minett TS, Thomas A, Wilkinson LM, et al. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003;18:988-93.
13. Bickel U, Thomsen T, Weber W, et al. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther 1991;50:420-8.
14. Marino MR, Vachharajani NN. Drug interactions with irbesartan. Clin Pharmacokinet 2001;40:605-14.
15. Iraqi A, Hughes TL. A case report of paranoid delusion with galantamine use (letter). J Am Geriatr Soc 2005;53:2036-7.
16. Brembilla-Perrot B, Regent MC, Hanesse B, et al. [Paroxysmal atrioventricular block due to anticholinesterase therapy]. Arch Mal Coeur Vaiss 2004;97:1265-7.
17. Inouye SK. Delirium in older persons. N Engl J Med 2006;354:1157-65.
18. Baraka A, Harik S. Reversal of central anticholinergic syndrome by galanthamine. JAMA 1977;238:2293-4.
19. Wang MH, Tseng CD, Bair SY. Q-T interval prolongation and pleomorphic ventricular tachyarrhythmia ('Torsade de pointes') in organophosphate poisoning: report of a case. Hum Exp Toxicol 1998;17:587-90.
20. Fitzpatrick AP, Lee RJ, Epstein LM, Lesh MD, Eisenberg S, Sheinman MM. Effect of patient characteristics on the yield of prolonged baseline head-up tilt testing and the additional yield of drug provocation. Heart 1996;76:406-11.
21. Bordier P, Lanusse S, Garrigue S, et al. Causes of syncope in patients with Alzheimer's disease treated with donepezil. Drugs Aging 2005;22: 687-94.
22. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001;43:1-45.
23. Martins JB, Zipes DP, Lund DD. Distribution of local repolarization changes produced by efferent vagal stimulation in the canine ventricles. J Am Coll Cardiol 1983;2:1191-9.
24. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia (letter). Int J Clin Pract Suppl 2002;Jun:45-63.
25. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.